Hepatitis and Diclofenac


Hepatitis Symptoms and Causes

Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver.

Viruses cause most cases of Hepatitis. The type of Hepatitis is named for the virus that causes it; for example, Hepatitis A, Hepatitis B or Hepatitis C. Drug or alcohol use can also cause Hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver.

Some people who have Hepatitis have no symptoms. Others may have

  • Loss of appetite
  • Nausea and vomiting
  • Diarrhea
  • Dark-colored urine and pale bowel movements
  • Stomach pain
  • Jaundice, yellowing of skin and eyes

Some forms of Hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer.

Sometimes Hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes Hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

Check out the latest treatments for hepatitis

hepatitis treatment research studies

Diclofenac clinical trials, surveys and public health registries

Find Drug Side Effect reports

Diclofenac Side Effects

Renal Failure Acute (154)
Abdominal Pain (139)
Diarrhoea (136)
Vomiting (128)
Dyspnoea (103)
Haemoglobin Decreased (103)
Gastrointestinal Haemorrhage (102)
Nausea (88)
Blood Creatinine Increased (88)
Anaemia (86)
Malaise (83)
Dehydration (82)
Pruritus (79)
Abdominal Pain Upper (77)
Blood Urea Increased (76)
Dizziness (72)
Gastric Ulcer (68)
Gastrointestinal Disorder (68)
Haematemesis (64)
Anaphylactic Reaction (62)
Pyrexia (61)
Erythema (60)
Fatigue (60)
Pain (60)
Hypotension (57)
Melaena (56)
Embolia Cutis Medicamentosa (54)
Chest Pain (54)
Arthralgia (53)
Rash (53)
Oedema Peripheral (51)
Asthenia (50)
Loss Of Consciousness (49)
Alanine Aminotransferase Increased (49)
Fall (48)
Headache (47)
Blood Alkaline Phosphatase Increased (47)
Metabolic Acidosis (46)
Gastritis (46)
Renal Failure (45)
Cardiac Arrest (44)
Confusional State (43)
Back Pain (43)
C-reactive Protein Increased (43)
Convulsion (43)
Urticaria (43)
Blood Pressure Decreased (41)
Weight Decreased (41)
Peritonitis (41)
Aspartate Aminotransferase Increased (40)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

After given the Hepatitis B vaccine- I had sore throat, chills, body aches, fever, congestion, and was bedridden and couldn't function for 3-4 days. MD gave me levaquin and Mucinex afterwards.

Cathy - same here, call me, Martin 513-681-1000 if you like to discuss and compare notes.


I injected diclofenac injection without any accident

Im general practioner i gave on intra mascular diclofenac for fever and body and about 8 or less he is dead inspite of using diclofeac tablet before and there is no prblem

Month ago I had oral sex and i am affraid of hepatitis b. What are the chances to get it on this way?

My boyfriend's wife has hepatitis B (she is in the states). He is immunized since year 2009. We are working here abroad and does unprotective sex. Last night, he traveled back to his country for vacation. If he have sex with his wife using a condom t

Want to know if my efforts of geeting into the health field are limited due to hepc?

What is an effective alternative to diclofenac ?

What is cytolytic hepatitis? I've been on subuxone for 6 years and also have tested positive for hepatitis C.

On 4/25/2006, I took the first of the three Hepatitis B shots. I suddenly had flu like symptoms which lasted for ever. I started getting really weak. I would eventually start losing weight. I went from 269 down to 118. I was diagnosed with Dermatomy

After given the Hepatitis B vaccine- I had sore throat, chills, body aches, fever, congestion, and was bedridden and couldn't function for 3-4 days. MD gave me levaquin and Mucinex afterwards.

Avelox taken in early March has caused me to have severe hepatitis. ALT and AST counts are in the thousands. Jaundice went away and bilirubin is normal now. All scans were negative, but a liver biopsy showed scarring and inflamation. ALT and AST star

Due to elevated liver enzyme levels and an elevated ANA, my previous doctor gave me a diagnosis of autoimmune hepatitis. After reviewing my charts, my current doctor believes that it was an autoimmune response to 3 back-to-back courses of amoxicillin

Had RhoGAM after childirth in 1972 and 1975. In 1992 I was diagnosed with hepatitis C. I now have stage 3 liver fibrosis and inflammation. I went through interferon-ribavirin treatment for hepatitis C recently, but did n

Headaches, very tired, skin rash which was very itchy, yellowing of skin and eyes, liver damage to 90% requiring hospitalisation, diagnosed as autoimmune hepatitis.

How can be ferriprox used with thalassemic hepatitis c patients?

Hy,doc. prescribed me mecobalamine injections one month ago now i diagnosed a hepatitis,is it due to mecobalamine?

Hy,me aksi wants to know can mecobalamine cause hepatitis

I am taking mexium 20 mg regularly for last 1.5 years. Recent blood test have shown high level of liver enzymes . I am a non drinker and have never had any jaundice or any immunisation of hepatitis. Nexium definately messed up my healthy liver

Hepatitis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Conditions: Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention: Drug: Peginterferon Alfa-2a plus Ribavirin
Outcome Measures: To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys®) plus ribavirin (RBV) for sustained virological response (SVR) in HBV-coinfected versus monoinfected chronic Hepatitis C (CHC) patients;   To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys®) plus ribavirin (RBV) on the reduction of HCV viremia after 24 and 48 weeks of treatment (depending on genotype) in coinfected versus monoinfected CHC patients;   To demonstrate the efficacy of PEG-IFN alfa-2a plus RBV in dual chronic Hepatitis C and B on:;   1) the biochemical response rate;   2) the score of histologic change;   3) serum HBV DNA disappearance;   4) HBsAg disappearance;   5) combined response of HBV DNA disappearance and normalization of ALT;   6) end of treatment virological response;   To assess the influence of serum HBV load on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT;   To assess the influence of HBV genotype on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT;   To assess the safety profile of the PEG-IFN alfa-2a plus RBV combination therapy in dual chronic Hepatitis C and B
2 Unknown  Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs
Condition: Vaccine Response Impaired
Intervention: Biological: Hepatitis A vaccine
Outcome Measures: seroconversion after the first dose/doses of Hepatitis A vaccine;   seroconversion rates after three doses of Hepatitis A vaccine
3 Recruiting De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation
Condition: De Novo Autoimmune Hepatitis
Interventions: Other: Pediatric transplant subject with d-AIH;   Other: Pediatric transplant subject with acute rejection;   Other: Pediatric transplant subject with chronic rejection;   Other: Adult non-transplant patients with auto-immune Hepatitis;   Other: Adult non-transplant subjects with chronic Hepatitis C virus;   Other: Pediatric control subjects
Outcome Measures: Liver Allograft Loss;   Need for Transplantation
4 Unknown  Adolescents' Response to Hepatitis B Vaccine Booster Dose
Condition: Hepatitis B
Intervention: Biological: Hepatitis B vaccine
Outcome Measure: anti-HBSAg titers
5 Recruiting Therapeutic Option for Hepatitis B and C: a French Cohort
Conditions: Viral Hepatitis B;   Viral Hepatitis C
Outcome Measures: To improve quality and effectiveness of medical care in Hepatitis B or C taking into account new treatment options and host characteristics;   To describe the epidemiology of HBV and HCV chronic infections in a context where the screening and early diagnosis of viral infection and genetic biomarkers research are increasing and evolving;   To obtain original data on efficacy and safety of new Hepatitis treatments in real‐life with long term follow‐up, allowing the estimation of the public‐health impact of these treatments in terms of reduction of morbidity or mortality.;   Cross‐disciplinary and translational research on Hepatitis based on a scientific/clinical expert network and a biobank creation;   To offer outstanding competency and resources for the design of clinical trials on specific sub‐populations and postmarketing (phase IV) studies;   To elaborate and compare cost‐effectiveness strategies for the management and treatment per patient class
6 Not yet recruiting PCV13 + Hepatitis A Vaccine for Adults
Conditions: Measurement of Immune Response to Prevenar13;   Measurement of Immune Response to Hepatitis A
Interventions: Biological: Prevenar13;   Biological: Hepatitis A vaccine
Outcome Measures: Immune response to PCV13;   Immune response to Hep A vaccine
7 Recruiting Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
Condition: Hepatitis B
Interventions: Drug: Entecavir prophylaxis;   Drug: Therapeutic entecavir
Outcome Measures: the incidence of Hepatitis B virus reactivation and Hepatitis B virus reactivation related Hepatitis;   the incidence of Hepatitis B virus maintained response, the incidence of Hepatitis B virus sustained response, the incidence of Hepatitis B virus relapse and Hepatitis B virus relapse related Hepatitis
8 Not yet recruiting Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
Condition: Hepatitis A
Intervention: Other: Data collection
Outcome Measures: Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HAV;   Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HBV (Hepatitis B core antibody [anti-HBc], Hepatitis B surface antigen [HBsAg]) and Hepatitis B surface antibody (anti-HBs);   Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for Pertussis antibodies;   Assesment of the difference in HAV, HBV and B. pertussis seropositivity rates among - Socioeconomic strata, - Regions, - Age groups, - Genders, - Risk groups, - Vaccination status for B. pertussis (if available)
9 Recruiting Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
Condition: Exposure to Hepatitis B Virus
Interventions: Drug: HBsAg;   Biological: PreS HBsAg;   Biological: Advax-1(TM);   Biological: Advax-2(TM);   Biological: Advax-3(TM);   Biological: Alum
Outcome Measures: Safety;   Hepatitis B surface antibody geometric mean titer;   T cell responses;   Efficacy
10 Unknown  Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery
Conditions: Varicella;   Hepatitis A
Interventions: Biological: Varicella Vaccine;   Biological: Hepatitis A Vaccine
Outcome Measures: Immunogenicity: General seroconversion rate 45 days following immunization. Safety: General rate of local and systemic adverse events after immunization according to definition established by Brighton Collaboration Group;   Degree and duration of local and systemic adverse events after immunization according to the Brighton Collaboration Group recommendations.;   Seroconversion rates and number of local and systemic adverse events after immunization according to delivery system (needle-free injector or syringe with needle) for each dose tested;   Actual volume administered intradermally according to the delivery system (needle-free injector or syringe with needle) for each fractional dose tested;   Participants' parents or legal guardians acceptability according to the delivery system (needle-free injector or syringe with needle) for each dose tested;   Distribution of vaccine jet evaluated through ultrasound for the needle-free injector group
11 Unknown  Association Between Hepatitis C Infection and Renal Cell Carcinoma
Conditions: Hepatitis C;   Renal Cell Carcinoma;   Colorectal Cancer
Intervention: Other: Hepatitis C testing
Outcome Measure: Prevalence of Hepatitis C in renal cell carcinoma patients
12 Unknown  Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load
Condition: Chronic Hepatitis B
Intervention: Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Outcome Measures: The primary objective is to demonstrate the efficacy of combination therapy (Peg-IFN and adefovir or Peg-IFN and tenofovir) for inducing loss of HBsAg compared to no-treatment in HBeAg negative chronic Hepatitis B patients with low viral load.;   The secondary objectives are to evaluate: a. the rate of HBsAg loss and anti-HBs seroconversion, b. To establish predictive markers at baseline and during the first 12 weeks of treatment for response of primary and secondary endpoints.
13 Recruiting Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Conditions: Hepatitis B;   Liver Transplantation
Intervention: Drug: Hepatitis B immune globulin
Outcome Measures: HBV recurrence;   HBsAb pre-infusion levels (through levels before each Niuliva administration);   Safety and tolerance
14 Unknown  Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Conditions: Chronic Hepatitis B;   Chronic Hepatitis D
Intervention: Drug: pegylated IFN alfa-2b plus ribavirin
Outcome Measures: the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic Hepatitis D and B;   the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic Hepatitis D and B on: The biochemical response rate;   The degree of histologic change
15 Not yet recruiting Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)
Conditions: Hepatitis B;   Hepatitis A
Intervention: Procedure: Blood sampling
Outcome Measures: Immunogenicity with respect to components of the study vaccine in terms of antibody titres;   Occurrence of Serious adverse events (SAEs)
16 Recruiting Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
Conditions: Alcoholic Hepatitis;   Alcoholic Cirrhosis
Intervention: Procedure: Liver transplantation
Outcome Measures: Non-inferiority of alcohol relapse in early liver transplantation for severe alcoholic Hepatitis as compared to patients transplanted for alcoholic cirrhosis.;   Validation of the survival benefit of transplanted patients as compared to non-transplanted patients with severe alcoholic Hepatitis;   Reproducibility of an algorithm of selection for candidates to liver transplantation;   Incidence of alcohol relapse;   Pattern of alcohol relapse in the two groups of transplanted patients
17 Not yet recruiting Surveillance and Treatment of Prisoners With Hepatitis C
Condition: Hepatitis C
Intervention: Drug: Sofosbuvir and ribavirin
Outcome Measures: Hepatitis C virus (HCV) incidence;   Hepatitis C virus prevalence;   SVR12;   ETR;   Rapid Virological Response (RVR);   Very rapid virological response (vRVR);   Treatment adherence;   Number of patients with adverse events;   Treatment uptake;   On-treatment change in illicit drug use;   HCV reinfection rate
18 Recruiting Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
Conditions: Human Immunodeficiency Virus;   Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention: Drug: antiretroviral drugs
Outcome Measures: Incidence of grade 3 or 4 transaminase elevations;   Incidence of grade 3 or 4 bilirubin elevations;   Percentage of patients with undetectable HIV RNA at the end of follow-up;   CD4 cell count at the end of follow-up
19 Unknown  Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
Conditions: Hepatitis C;   Hepatitis B
Intervention: Drug: Pegasys; Copegus.
Outcome Measures: Phase I - To evaluate the prevalence of insulin resistance in patients with Hepatitis C without cirrhosis and compare it to that observed in patients with Hepatitis B also without cirrhosis.;   Phase II - Interventional phase - To evaluate the effect of anti-viral therapy on insulin resistance, determined by the OGTT method, in patients with Hepatitis C found to have insulin resistance pre-treatment.;   - To evaluate the safety, efficacy and tolerability of Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naïve patients with chronic Hepatitis C (CHC).
20 Recruiting Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Conditions: Hepatitis;   HIV;   Liver Cancer
Outcome Measure: